BioLineRx Ltd.
BLRX Healthcare Biotechnology
BioLineRx Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 95.9% from fiscal 2024. In the quarter to June 2026, revenue fell 3.29%, EPS grew 23.0%, free cash flow fell 1,827.7% and total debt fell 40.2%, each against the same quarter a year earlier.
Follow BLRX
BioLineRx Ltd. (BLRX) Altman Z-score
BioLineRx Ltd.'s Altman Z-score for fiscal 2025 is −13.80, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −13.80 | 0.82 |
| FY2024 | −14.62 | (4.85) |
| FY2023 | −9.77 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.28 | — | 0.34 | |
| Retained earnings / total assets | (9.80) | — | −13.72 | |
| EBIT / total assets | (0.25) | — | −0.83 | |
| Market value of equity / total liabilities | 0.65 | — | 0.39 | |
| Sales / total assets | 0.03 | — | 0.03 | |
| Altman Z-score | Distress zone | −13.80 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −30.40 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| GDTC CytoMed Therapeutics Limited compare | 6.8× |
| TPST Tempest Therapeutics, Inc. compare | −2.0× |
| KPRX Kiora Pharmaceuticals, Inc. compare | −3.2× |
| BLRX BioLineRx Ltd. | −13.8× |
| PHIO Phio Pharmaceuticals Corp. compare | −18.2× |
| LSTA Lisata Therapeutics, Inc. compare | −43.9× |
| BIVI BioVie Inc. compare | — |
| LTRN Lantern Pharma Inc. compare | — |
| TOVX Theriva Biologics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets